Overview

Safety and Efficacy of SPD503 in Treating ADHD in Children and Adolescents Aged 6-17

Status:
Completed

Trial end date:
2004-10-07

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the efficacy of SPD503 compared to placebo in the treatment of children and adolescents aged 6-17 with ADHD.

Phase:

Phase 3

Details

Lead Sponsor:

Shire

Treatments:

Guanfacine